Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 33,137 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Psoriasis, Plaque-type Psoriasis
Interventions: Apremilast 10mg, Apremilast 20mg, Apremilast 30 mg, Placebo, Apremilast 30mg; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 20
States / cities: Fresno, California • Los Angeles, California • Redwood City, California + 16 more

Conditions: Bipolar I Disorder, Bipolar II Disorder
Interventions: ABBV-932, Placebo for ABBV-932; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 32
States / cities: Dothan, Alabama • Anaheim, California • Colton, California + 28 more

Conditions: Hot Flashes, Prostate Cancer
Interventions: oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill; Dietary Supplement · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 20
States / cities: Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more

Conditions: Opioid Dependence, Opioid Use Disorder (OUD)
Interventions: VK4-116, Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: CTP-692, Placebo; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Prostate Cancer
Interventions: Abiraterone acetate, Placebo, Prednisone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,088 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 48
States / cities: Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 45 more

Conditions: Endometriosis, Endometriosis-related Pain
Interventions: Metronidazole Oral, Placebo; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Muscular Dystrophy, Duchenne
Interventions: Edasalonexent, Placebo; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 4 Years to 7 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Orlando, Florida + 2 more

Conditions: Schizophrenia
Interventions: AMG 747, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Anaheim, California • Cerritos, California • Culver City, California + 15 more

Conditions: Healthy
Interventions: RTA 408 Lotion 0.5%, 1%, 3%, Lotion vehicle/placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension
Interventions: Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo; Drug
Lead sponsor: George Medicines PTY Limited; Industry
Eligibility: 18 Years and older
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 23
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more

Conditions: Diffuse Glioma, Malignant Glioma
Interventions: Biospecimen Collection, Computed Tomography, Eflornithine, Magnetic Resonance Imaging, Polyamine Transport Inhibitor AMXT-1501 Dicaprate, Resection, Microdialysis, Placement; Procedure · Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Schizophrenia
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: Irvine, California • San Diego, California

Conditions: Post Operative Pain, Spinal Surgery
Interventions: Methadone, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 72 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Contraception, Inhalation of Nitrous Oxide
Interventions: In-office Transcervical Sterilization (Essure®), Standard Oral pain medications, Intramuscular Ketorolac, Placebo pills, Oxygen, Nitrous Oxide; Procedure · Drug · Other
Lead sponsor: University of New Mexico; Other
Eligibility: 21 Years and older · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Tuberous Sclerosis Complex
Interventions: Early Vigabatrin, Delayed Vigabatrin (Placebo); Drug
Lead sponsor: Martina Bebin; Other
Eligibility: 1 Day to 6 Months
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Essential Tremor
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 26
States / cities: Anniston, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 23 more

Conditions: Systolic Heart Failure
Interventions: Probenecid 1 gr oral twice daily, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Colorectal Disorders, Observation of Neuromuscular Block
Interventions: 0.2% ropivacaine, Saline; Drug
Lead sponsor: Stamford Hospital; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Stamford, Connecticut

Conditions: Hyperlipidemia
Interventions: Evolocumab, Placebo to Evolocumab; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 55
States / cities: Birmingham, Alabama • Tucson, Arizona • Malvern, Arkansas + 48 more

Conditions: Nephrolithiasis, Calcium Oxalate, Nephrolithiasis, Calcium Phosphate
Interventions: Tolvaptan, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pain, Postoperative, Nerve Block, Robotic Surgical Procedures
Interventions: Bupivacain, Ultrasound-guided transversus abdominus plane block, Laparoscopic-guided transversus abdominus plane block; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Neoplasms, Prostate
Interventions: Dutasteride, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 8,231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 297
States / cities: Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 236 more

Conditions: Skin Inflammation
Interventions: Broccoli, mustard, vitamin C, Placebo; Dietary Supplement
Lead sponsor: Appalachian State University; Other
Eligibility: 25 Years to 57 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Search by objective public record fields.

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

VK4-116 Phase I Study With Food-Effect

Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery

Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy

20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

RTA 408 Lotion in Healthy Volunteers

Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

Antipsychotic Effects of Oxytocin

Methadone to Reduce Chronic Opioid Use After Major Spine Surgery: The MEND Pilot Feasibility Study

Nitrous Oxide for Pain Management During In-office Transcervical Sterilization

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

A Study to Evaluate SAGE-217 in Participants With Essential Tremor

Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure

Effectiveness of Transverse Abdominus Plane Catheter Blocks to Patient-controlled Analgesia in Laparoscopic Colon Resections

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study

Use of Perioperative Pain Blocks In Urological Surgery

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

Broccoli Seed Extract and Skin Health